Work

429TiP IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC

Year: 2016

Type: article

Study design: Study Protocol

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(21)00587-1

Authors: C. Zhou, N. Altorki, E. Vallieres, E. Felip, Y. Zuo, M. Howland, F. Xia, T. Hoang, A. Sandler, H. Wakelee

Institutions: Tongji University, Shanghai Pulmonary Hospital, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Vall d'Hebron Hospital Universitari, Roche (China), Genentech, Stanford Medicine, Stanford University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2587519285

FWCI:

Cites:

Cited by:

Related to: 10